ThornalleyP.J., BattahS., AhmedN., KarachaliasN., AgalouS., Babaei-JadidiR.Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry.Biochem J2003; 375(Pt 3): 581–92.
2.
KauppilaL., PolakJ., CupplesL., HannanM., KielD., WilsonP.New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study.Atherosclerosis1997; 132: 245–50.
3.
LindenT., CohenA., DeppischR., KjellstrandP., WieslanderA.3,4-dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis.Kidney Int2002; 62(2): 697–703.
4.
McIntyreN.J., FluckR.J., McIntyreC.W., TaalM.W.Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3.Clin J Am Soc Nephrol2011; 6(10): 2356–63.
5.
MeerwaldtR., HartogJ.W., GraaffR., HuismanR.J., LinksT.P., den HollanderN.C.Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients.J Am Soc Nephrol2005; 16(12): 3687–93.
6.
KoyamaY., TakeishiY., ArimotoT., NiizekiT., ShishidoT., TakahashiH.High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure.J Card Fail2007; 13(3): 199–206.
7.
WautierM.P., MassinP., GuillausseauP.J., HuijbertsM., LevyB., BoulangerE.N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients.Diabetes Metab2003; 29(1): 44–52.
